Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more
Shanghai Hile Bio-tech (603718) - Net Assets
Latest net assets as of September 2025: CN¥1.70 Billion CNY
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has net assets worth CN¥1.70 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.80 Billion) and total liabilities (CN¥105.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.70 Billion |
| % of Total Assets | 94.12% |
| Annual Growth Rate | 11.66% |
| 5-Year Change | 77.01% |
| 10-Year Change | 76.81% |
| Growth Volatility | 20.95 |
Shanghai Hile Bio-tech - Net Assets Trend (2011–2024)
This chart illustrates how Shanghai Hile Bio-tech's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Hile Bio-tech (2011–2024)
The table below shows the annual net assets of Shanghai Hile Bio-tech from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.70 Billion | +44.98% |
| 2023-12-31 | CN¥1.17 Billion | +5.74% |
| 2022-12-31 | CN¥1.11 Billion | +12.54% |
| 2021-12-31 | CN¥987.19 Million | +2.60% |
| 2020-12-31 | CN¥962.20 Million | -3.06% |
| 2019-12-31 | CN¥992.57 Million | -3.24% |
| 2018-12-31 | CN¥1.03 Billion | -4.57% |
| 2017-12-31 | CN¥1.07 Billion | +6.92% |
| 2016-12-31 | CN¥1.01 Billion | +4.36% |
| 2015-12-31 | CN¥963.31 Million | +72.48% |
| 2014-12-31 | CN¥558.50 Million | +11.55% |
| 2013-12-31 | CN¥500.66 Million | +7.01% |
| 2012-12-31 | CN¥467.89 Million | +15.32% |
| 2011-12-31 | CN¥405.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Hile Bio-tech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 918.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥556.71 Million | 35.68% |
| Common Stock | CN¥657.90 Million | 42.16% |
| Other Components | CN¥345.87 Million | 22.16% |
| Total Equity | CN¥1.56 Billion | 100.00% |
Shanghai Hile Bio-tech Competitors by Market Cap
The table below lists competitors of Shanghai Hile Bio-tech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xinjiang Tianshun Supply Chain Co Ltd
SHE:002800
|
$234.39 Million |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
$234.41 Million |
|
Lydia Yesil Enerji Kaynaklari A.S.
IS:LYDYE
|
$234.49 Million |
|
Guilin Tourism Corp Ltd
SHE:000978
|
$234.55 Million |
|
Duni AB (publ)
PINK:DUNNF
|
$234.27 Million |
|
Talon Capital Corp. Class A Ordinary Shares
NASDAQ:TLNC
|
$234.19 Million |
|
Jacquet Metal Service SA
PA:JCQ
|
$234.17 Million |
|
Hudson Technologies Inc
NASDAQ:HDSN
|
$234.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Hile Bio-tech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,216,978,966 to 1,560,478,382, a change of 343,499,416 (28.2%).
- Net income of 171,180,295 contributed positively to equity growth.
- Dividend payments of 21,573,174 reduced retained earnings.
- Other comprehensive income increased equity by 266,415,610.
- Other factors decreased equity by 72,523,315.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥171.18 Million | +10.97% |
| Dividends Paid | CN¥21.57 Million | -1.38% |
| Other Comprehensive Income | CN¥266.42 Million | +17.07% |
| Other Changes | CN¥-72.52 Million | -4.65% |
| Total Change | CN¥- | 28.23% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Hile Bio-tech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.05x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.42x to 2.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.76 | CN¥4.86 | x |
| 2012-12-31 | CN¥0.92 | CN¥4.86 | x |
| 2013-12-31 | CN¥0.96 | CN¥4.86 | x |
| 2014-12-31 | CN¥1.13 | CN¥4.86 | x |
| 2015-12-31 | CN¥1.65 | CN¥4.86 | x |
| 2016-12-31 | CN¥1.49 | CN¥4.86 | x |
| 2017-12-31 | CN¥1.69 | CN¥4.86 | x |
| 2018-12-31 | CN¥1.49 | CN¥4.86 | x |
| 2019-12-31 | CN¥1.65 | CN¥4.86 | x |
| 2020-12-31 | CN¥1.64 | CN¥4.86 | x |
| 2021-12-31 | CN¥1.56 | CN¥4.86 | x |
| 2022-12-31 | CN¥1.77 | CN¥4.86 | x |
| 2023-12-31 | CN¥1.94 | CN¥4.86 | x |
| 2024-12-31 | CN¥2.37 | CN¥4.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Hile Bio-tech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.97%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 63.16%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.17x
- Recent ROE (10.97%) is above the historical average (10.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 26.44% | 41.24% | 0.52x | 1.24x | CN¥66.70 Million |
| 2012 | 24.05% | 36.21% | 0.55x | 1.20x | CN¥65.76 Million |
| 2013 | 24.34% | 37.26% | 0.53x | 1.23x | CN¥69.99 Million |
| 2014 | 18.50% | 35.48% | 0.44x | 1.20x | CN¥46.50 Million |
| 2015 | 10.32% | 30.14% | 0.26x | 1.34x | CN¥3.00 Million |
| 2016 | 8.71% | 24.91% | 0.23x | 1.51x | CN¥-12.62 Million |
| 2017 | 10.63% | 37.46% | 0.19x | 1.50x | CN¥6.78 Million |
| 2018 | 2.02% | 8.37% | 0.15x | 1.66x | CN¥-84.25 Million |
| 2019 | -2.49% | -9.50% | 0.16x | 1.60x | CN¥-132.49 Million |
| 2020 | -3.04% | -12.41% | 0.15x | 1.69x | CN¥-137.99 Million |
| 2021 | 5.36% | 15.51% | 0.19x | 1.83x | CN¥-46.70 Million |
| 2022 | 10.66% | 40.54% | 0.20x | 1.33x | CN¥7.57 Million |
| 2023 | 5.17% | 26.12% | 0.15x | 1.36x | CN¥-58.83 Million |
| 2024 | 10.97% | 63.16% | 0.15x | 1.17x | CN¥15.13 Million |
Industry Comparison
This section compares Shanghai Hile Bio-tech's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Hile Bio-tech (603718) | CN¥1.70 Billion | 26.44% | 0.06x | $234.31 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |